Comparison of therapeutic effects on type 2 diabetes mellitus between GLP-1 receptor stimulant and DPP-4 inhibitor
10.3969/j.issn.1008-0074.2017.04.23
- VernacularTitle:GLP-1受体激动剂与DPP-4抑制剂对2型糖尿病的疗效对比
- Author:
Qiaoqiong CHEN
- Keywords:
Glucagon-like peptide 1;
Dipeptidyl peptidase 4;
Diabetes mellitus,type 2
- From:
Chinese Journal of cardiovascular Rehabilitation Medicine
2017;26(4):434-437
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To compare therapeutic effects on type 2 diabetes mellitus (T2DM) between glucagon-like peptide 1 (GLP-1) receptor agonist and dipeptidyl peptidase-4 (DPP-4) inhibitor.Methods: A total of 96 T2DM patients treated in our hospital from Jan 2015 to Jan 2016 were selected.According to random number table method, patients were randomly and equally divided into GLP-1 receptor stimulant group (GLP-1 group, received GLP-1 receptor stimulant liraglutide treatment) and DPP-4 inhibitor group (DPP-4 group, received DPP-4 inhibitor sitagliptin treatment), both groups were treated for 18 weeks.Levels of fasting blood glucose (FBG) and 2h postprandial blood glucose (2hPG) were measured and compared, and incidence of adverse reactions were compared between two groups before and after treatment.Results: Compared with before treatment, after 18-week treatment, there were significant reductions in levels of FBG and 2hPG in both groups, P<0.05 or <0.01.Compared with DPP-4 group after treatment, there were significant reductions in levels of FBG [(7.48±0.45) mmol/L vs.(6.64±0.28) mmol/L] and 2hPG [(11.15±1.01) mmol/L vs.(9.26±1.82) mmol/L] in GLP-1 group, P<0.05 both.There was no significant difference in incidence rate of total adverse reactions (29.2% vs.33.3%) between GLP-1 group and DPP-4 group, P=0.078.Conclusion: Compared with DPP-4 inhibitor, GLP-1 receptor stimulant is better in controlling blood glucose and reducing body weight in T2DM patients, which is worth extending.
